Y. Ohta

发表

Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor

Biching Sang, P. Farrell, Lihong Shi, 2013, Molecular Cancer Therapeutics.

Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model

T. Ishikawa, Y. Ohta, Akiko Nakayama, 2013, Journal of Cancer.

A comparative study of the conversion of 7-hydroxycholesterol in rabbit, guinea pig, rat, hamster, and chicken

Y. Ohta, T. Setoguchi, K. Kondo, 2002, Steroids.

STRUCTURAL ANALYSIS OF THE MECHANISM OF INHIBITION AND ALLOSTERIC ACTIVATION OF THE KINASE DOMAIN OF HER 2

Toshimasa Tanaka, Biching Sang, J. Yano, 2011 .

Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603.

Y. Ohta, H. Makino, S. Fukuda, 1997, Immunopharmacology.

Immunomodulating and articular protecting activities of a new anti-rheumatic drug, TAK-603.

Y. Ohta, T. Sohda, A. Baba, 1996, Immunopharmacology.

Vasoinhibitory effects of NC 1005 and NC 1006, new synthesized antiarrhythmic agents, in isolated rat aorta.

I. Kodama, Y. Ohta, S. Shibata, 1994, General pharmacology.

Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

T. Taniguchi, Toshimasa Tanaka, J. Yano, 2011, Journal of medicinal chemistry.

Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.

Toshimasa Tanaka, T. Ohashi, T. Ishikawa, 2012, Journal of medicinal chemistry.

Synthesis and anti-influenza virus activity of novel pyrimidine derivatives.

T Suzutani, T. Suzutani, Y. Ohta, 1999, Antiviral research.

Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect.

Y. Ohta, T. Sohda, A Baba, 1996, Journal of medicinal chemistry.

HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285

T. Ishikawa, H. Banno, Y. Ohta, 2014, Oncoscience.

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

Yoshikazu Ohta, Tomoyasu Ishikawa, Andy Jennings, 2011, The Journal of Biological Chemistry.

Increased phosphorylation of Akt in triple‐negative breast cancers

Sei Yoshida, Y. Ohta, Y. Tokuda, 2007, Cancer science.

TAK‐603 selectively suppresses Th1‐type cytokine production and inhibits the progression of adjuvant arthritis

Y. Ohta, T. Sohda, H. Makino, 1997, Immunology.

Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors.

Yoshikazu Ohta, Tomoyasu Ishikawa, Terufumi Takagi, 2013, ACS medicinal chemistry letters.

Studies on disease-modifying antirheumatic drugs. II. Synthesis and activity of the metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quino line-3-carboxylate (TAK-603).

Y. Ohta, T. Sohda, A. Baba, 1998, Chemical & pharmaceutical bulletin.

Studies on Disease-Modifying Antirheumatic Drugs. Part 2. Synthesis and Activity of the Metabolites of Ethyl 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-2- (1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603).

Y. Ohta, T. Sohda, A. Baba, 1998 .

Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors.

Tomohiro Ohashi, Yoshikazu Ohta, Tomoyasu Ishikawa, 2013, Bioorganic & medicinal chemistry.

Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy.

Toshimasa Tanaka, Y. Ikeda, T. Ishikawa, 2012, Bioorganic & medicinal chemistry.